Micro-Invasive Glaucoma Surgery Device (MIGS) for Clinical Trial Program Supports - Medical / Health Care - Clinical Services

FromiSTAR Medical SA

SHARE

A comprehensive clinical trial program supports the development of MINIject^®, with positive combined results at two years from the STAR-I and STAR-II clinical trials shown below. ¹

Most popular related searches

intraocular pressure

clinical program

eye irritations

cataract surgery

skin sensitization

glaucoma surgery

healthcare service

clinical support

skin irritation

medical procedure

surgery clinical

Intraocular Pressure (IOP)

Meaningful IOP reduction to
~40% mean IOP reduction after two years
Trials designed with stand-alone procedure

Medication

Nearly half of patients medication-free after two years
Medication use reduced by 45% two years post-procedure
Significant reduction or elimination of medication side-effects such as eye irritation/burning, eye pain, and skin sensitivity/irritation around the eye ²

Reduced complications

Low re-intervention rate up to two years
Bleb-free and conjunctiva sparing procedure - no needling, no MMC required
Very low number of patients with >30% central endothelial cell density (ECD) loss at two years

Evidence-based data on safety and efficacy

More than 150 patients in clinical trials
11 trial centers throughout Europe, India and Latin America
MINIject assessed as stand-alone procedure- no enhancement of outcomes from joint cataract surgery
Published results after two-years of follow-up